Anita Turk, MD, discusses what she is most excited about regarding immunotherapy in the realm of colorectal cancer treatment.

Patients with ovarian clear cell carcinoma (OCCC) whose tumors have specific mutations in the PPP2R1A gene were found to have ...

According to the latest study from BCC Research, the "Cancer Immunotherapy: Technologies and Global Markets" is expected to ...

Organ transplant recipients with advanced cancer, an often overlooked group in cancer care, may benefit from immunotherapy ...

NASHVILLE, Tenn. (WTVF) — June is Cancer Immunotherapy Month. Immunotherapy drugs have been on the market for more than a ...

Patients with ovarian clear cell carcinoma (OCCC) whose tumors have specific mutations in the PPP2R1A gene were found to ...

Researchers led by John T. Wilson, Vanderbilt University associate professor of chemical and biomolecular engineering and ...

Gynecologic clear cell cancers are aggressive malignant neoplasms with low response rates to chemotherapy. Among patients ...

Scientists at UC Davis discovered a small genetic difference that could explain why humans are more prone to certain cancers ...

Invasive bladder cancer can be treated through immunotherapy involving Bacillus Calmette-Guérin (BCG), but some 40%-60% of ...

Dr. Brad Nelson has been named B.C. Cancer Victoria’s Lynda and Murray Farmer Immunotherapy Research Chair, which means he ...

A post hoc analysis of the BEATcc trial showed that atezolizumab plus chemotherapy and bevacizumab provided clinical benefit ...